Analysis of survival by tumor response.
- 1 November 1983
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 1 (11), 710-719
- https://doi.org/10.1200/jco.1983.1.11.710
Abstract
The common practice of comparing the survival of responders and nonresponders when reporting the results of cancer chemotherapy treatment is investigated. The usual method of comparing responders and nonresponders is biased in favor of responders, and these results are frequently misinterpreted as providing evidence that response prolongs survival, or that the treatment under study is effective. Two valid methods for comparing responders and nonresponders are discussed and recommendations are made concerning the analysis of survival by response. A comparison of survival by response category may be useful descriptively, but such a comparison should not be used for inference concerning treatment effectiveness.This publication has 4 references indexed in Scilit:
- Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lungCancer, 1982
- Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survivalCancer, 1982
- The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancerCancer, 1980
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977